Congress Advised n Top 100 List f Health Issues
The News Review:
- Congress Advised n Top 100 List f Health Issues
- Encorium says it will complete sale by midmonth
- Interferon Alpha Can Delay Full nset f Type I Diabetes Phase II …
Congress Advised n Top 100 List f Health Issues
Redrbit
As a part of the American Recovery and Reinvestment Act (ARRA) Congress directed the Institute of Medicine (IM) ?to recommend national priorities for research questions to be supported by CER (comparative effectiveness research) and ARRA funds. ?Issued on June 30 the IM?s ?Initial National Priorities for Comparative Effectiveness Research? report lays out a list of the top 100 medical issues to be addressed by Congress using the stimulus funds. ?Clinical research provides health care providers with information on the natural history of disease clinical presentations of disease and diagnostic and treatment options? according to the report. ?All too often the information necessary to inform these medical decisions is incomplete or unavailable resulting in more than half of the treatments delivered today without clear evidence of effectiveness. GA_googleFillSlotWithSize(”ca-pub-5440138744487553″ “News_Main_300×250″ 300 250);?This uncertainty contributes to great variability in managing clinical problems with costs and outcomes differing markedly across the country. ?The report provides a definition for CER as ?the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent diagnose treat and monitor a clinical condition or to improve the delivery of care. The report issues a ?list of priorities? to be focused on using the national investment for CER including:- Compare the effectiveness of treatment strategies for atrial fibrillation including surgery catheter ablation and pharmacologic treatment.
Encorium says it will complete sale by midmonth
Bizjournals.com
_50C67A5A4AA943A8A19E0BD53867EB45. said Wednesday that the sale of its U. clinical research organization business to Pierrel SpA originally expected to close Tuesday is now expected to close by July 15. -based Encorium (NASDAQ:ENC) also said the completion of the sale of its Encorium Y European subsidiary to an unnamed clinical research organization should be complete by the fourth quarter.
Interferon Alpha Can Delay Full nset f Type I Diabetes Phase II …
Science Daily (press release)
Research was conducted at The University of Texas Clinical Research Center at Memorial Hermann-Texas Medical Center which is part of the Center for Clinical and Translational Sciences at The University of Texas Health Science Center at Houston. Research subjects ages 3 to 25 diagnosed with type 1 diabetes within six weeks of enrollment were randomized to receive 5000 units of interferon alpha 30000 units of interferon alpha or placebo once daily for one year. Patients treated with 5000 units lost only 29 percent of their beta cell function compared to 48 percent for patients receiving 30000 units and 56 percent for patients receiving the placebo. Austin resident Jarod Wallquist 11 was 5 years old when he was diagnosed with type I diabetes and his mother Amy learned about Brod’s study. Jarod received the 5000 units of interferon alpha but neither she nor the researchers knew it at the time because of the double-blind nature of the study.
Related from Weightlossmonster: New Weight Loss Hope for People with Diabetes
Written by admin on July 2nd, 2009 with
no comments.
Read more articles on News.